The Wellcome Trust’s Jeremy Farrar is all but begging for action to shore up the failing antibiotics market.
- Decades of weak investment in antibiotics has left “perilously few” companies involved in antibiotic development—a market crisis unfolding alongside the rise of deadly drug-resistant superbugs.
- Farrar warns that there is currently no viable pathway to market for new antibiotics—and politicians are failing to address the problem.
